Arcturus Therapeutics Ltd (ARCT) Stock Price, Quote & News

Company Profile

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address orni...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 900 2660

Website: arcturusrx.com

Address:

10285 Science Center Drive, San Diego, United States

bigchouse May. 13 at 9:10 AM

$ARCT Andes Virus Outbreak on a Cruise Ship: Current Situation: CDC is responding to a deadly outbreak of Andes virus, a type of hantavirus, among passengers and crew of a cruise ship in the Atlantic Ocean. To date, no cases of Andes virus have been confirmed in the United States as a result of this outbreak. The risk of a pandemic caused by this outbreak and the overall risk to the American public and travelers remains extremely low. https://www.cdc.gov/hantavirus/situation-summary/index.html

0 · Reply

bigchouse May. 13 at 12:13 AM

$ARCT Just in time for the midterm elections. Cruise passengers question their rights as hantavirus health scare sparks worry https://www.foxnews.com/travel/cruise-passengers-question-rights-hantavirus-health-scare-sparks-worry-questions

0 · Reply

2PacalypseNow4Life May. 12 at 8:34 PM

$ARCT "ANSWER to28 Amended Complaint,, by AbbVie Inc., Priya Karmali, Capstan Therapeutics, Inc., S.P. Tanis Pharmachem Consulting LLC, Steven P. Tanis , COUNTERCLAIM against Arcturus Therapeutics, Inc., Rajesh Mukthavaram, Daiki Matsuda by AbbVie Inc., Priya Karmali, Capstan Therapeutics, Inc., S.P. Tanis Pharmachem Consulting LLC, Steven P. Tanis.(Pensabene, Lisa)".

1 · Reply

SuperGreenToday May. 12 at 7:13 PM

$ARCT Share Price: $8.36 Contract Selected: Dec 18, 2026 $10 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.07 – $0.09 Potential Upside: 55% ROI Time to Expiration: 219 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Dr_Feel_Good May. 12 at 6:33 PM

$ARCT was that the bottom after news of Makary being ousted from the FDA. https://www.cnbc.com/2026/05/12/trump-fda-commissioner-marty-makary-out.html?__source=iosappshare%7Ccom.facebook.Messenger.ShareExtension&brid=YWdncwG65bFSX_HCyYGWA0Iti5qs

1 · Reply

Choice79 May. 12 at 1:42 PM

$ARCT highly unlikely that Arct will work on the hantavirus. Costs a lot of money to start something like that and they are prioritizing all their cash on otc and cf.

1 · Reply

bigchouse May. 12 at 8:33 AM

$ARCT Maybe he will lead the work for a vaccine for the hantavirus? Dr. Moncef Slaoui is Chairman of the Board of Directors at Arcturus Therapeutics due to his extensive leadership experience in vaccine development and pharmaceutical innovation. He joined the board in June 2024 and was appointed Chair Designate in February 2025. His background includes: Serving as Chief Scientific Advisor to Operation Warp Speed, where he played a key role in accelerating the development of multiple COVID-19 vaccines. Nearly 30 years at GlaxoSmithKline (GSK), where he held leadership roles including Chairman of Global Vaccines, overseeing the development of 14 new vaccines such as Shingrix®, Cervarix®, and Mosquirix. Board experience at major biotech firms, including Moderna, Lonza Group AG, Vaxcyte, and Galvani. Arcturus highlighted his strategic expertise in drug and vaccine development as vital for advancing its mRNA pipeline, which includes programs for influenza, cystic fibrosis, etc..

0 · Reply

bigchouse May. 12 at 3:03 AM

$ARCT https://virological.org/t/complete-sequence-of-orthohantavirus-andesense-virus-swiss-resident-2026/1023

1 · Reply

OfficialStocktwitsUser May. 11 at 10:43 PM

$ARCT RSI: 47.75, MACD: 0.2365 Vol: 0.24, MA20: 8.70, MA50: 7.93 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

bigchouse May. 11 at 4:05 PM

$ARCT One the 17 American passengers evacuated from the MV Hondius tested positive for the hantavirus but is not showing any symptoms, U.S. health officials said late Sunday. https://apnews.com/article/hantavirus-cruise-ship-hondius-tenerife-1c43c66d2b0555cf946d9e57fc65f1d4

0 · Reply

Arcturus Therapeutics Holdings Earnings Call Transcript: Q1 2026

May 7, 2026, 4:01 PM EDT - 5 days ago

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

Apr 27, 2026, 4:01 PM EDT - 15 days ago

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026

Mar 23, 2026, 12:30 PM EDT - 7 weeks ago

Arcturus Therapeutics Holdings Transcript: The 38th Annual Roth Conference

2026-03-18T09:05:17.000Z - 2 months ago

Arcturus Therapeutics initiated with a Buy at B. Riley

Mar 11, 2026, 11:20 AM EDT - 2 months ago

Arcturus Therapeutics Holdings Transcript: Leerink Global Healthcare Conference 2026

Mar 5, 2026, 9:00 AM EST - 2 months ago

Arcturus Therapeutics to Attend Upcoming Investor Conference

2026-03-05T11:25:30.000Z - 2 months ago

Arcturus Therapeutics price target lowered to $21 from $66 at Canaccord

2026-03-04T12:55:37.000Z - 2 months ago

Arcturus Therapeutics price target lowered to $25 from $72 at Piper Sandler

2026-03-04T10:50:31.000Z - 2 months ago

Arcturus Therapeutics price target raised to $8 from $7 at Citi

Mar 3, 2026, 4:30 PM EST - 2 months ago

Arcturus Therapeutics Holdings Earnings Call Transcript: Q4 2025

Mar 3, 2026, 4:01 PM EST - 2 months ago

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress

2026-03-03T12:05:25.000Z - 2 months ago

Options Volatility and Implied Earnings Moves Today, March 03, 2026

AZO BBY TGT

Feb 17, 2026, 4:01 PM EST - 3 months ago

Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026

Feb 11, 2026, 10:30 AM EST - 3 months ago

Arcturus Therapeutics Holdings Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

2026-01-22T21:10:46.000Z - 3 months ago

Arcturus Therapeutics initiated with a Buy at Roth Capital

Jan 12, 2026, 8:15 PM EST - 4 months ago

Arcturus Therapeutics Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 5:30 PM EST - 4 months ago

Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

2026-01-06T11:21:09.000Z - 4 months ago

Arcturus Therapeutics price target lowered to $7 from $9 at Citi

2025-12-30T21:05:16.000Z - 4 months ago

Arcturus Therapeutics files $500M mixed securities shelf

2025-11-13T11:40:58.000Z - 6 months ago

Arcturus Therapeutics price target lowered to $9 from $12 at Citi

2025-11-11T11:40:12.000Z - 6 months ago

Arcturus Therapeutics price target lowered to $72 from $140 at Piper Sandler

Nov 10, 2025, 4:30 PM EST - 6 months ago

Arcturus Therapeutics Holdings Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:01 PM EST - 6 months ago

Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

2025-11-10T20:05:09.000Z - 6 months ago

Arcturus Therapeutics options imply 11.1% move in share price post-earnings

Nov 4, 2025, 4:01 PM EST - 6 months ago

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Oct 28, 2025, 4:01 PM EDT - 7 months ago

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025

2025-10-24T10:25:30.000Z - 7 months ago

Arcturus Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

Oct 22, 2025, 8:53 AM EDT - 7 months ago

Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results

Oct 22, 2025, 7:30 AM EDT - 7 months ago

Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program

Aug 11, 2025, 4:30 PM EDT - 9 months ago

Arcturus Therapeutics Holdings Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:01 PM EDT - 9 months ago

Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress

Jul 24, 2025, 4:01 PM EDT - 10 months ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Jun 30, 2025, 12:00 PM EDT - 11 months ago

Arcturus Therapeutics Holdings Transcript: Status Update

Jun 30, 2025, 11:00 AM EDT - 11 months ago

Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program

Jun 23, 2025, 8:30 AM EDT - 11 months ago

Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency

May 12, 2025, 4:30 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Earnings Call Transcript: Q1 2025

May 12, 2025, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress

Apr 22, 2025, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

Apr 16, 2025, 11:00 AM EDT - 1 year ago

Arcturus Therapeutics Holdings Transcript: Status Update

Apr 11, 2025, 12:00 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Transcript: Fireside Chat

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

Mar 12, 2025, 10:40 AM EDT - 1 year ago

Arcturus Therapeutics Holdings Transcript: Leerink’s Global Healthcare Conference 2025

Mar 6, 2025, 4:30 PM EST - 1 year ago

Arcturus Therapeutics Holdings Earnings Call Transcript: Q4 2024

Mar 6, 2025, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

Mar 5, 2025, 4:30 PM EST - 1 year ago

Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025

Feb 24, 2025, 4:01 PM EST - 1 year ago

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

Feb 14, 2025, 8:30 AM EST - 1 year ago

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

Feb 6, 2025, 10:30 AM EST - 1 year ago

Arcturus Therapeutics Holdings Transcript: Guggenheim SMID Cap Biotech Conference

Feb 4, 2025, 8:30 AM EST - 1 year ago

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

Jan 31, 2025, 3:00 AM EST - 1 year ago

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19

Jan 30, 2025, 4:01 PM EST - 1 year ago

Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference

Jan 15, 2025, 12:45 PM EST - 1 year ago

Arcturus Therapeutics Holdings Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 10, 2025, 8:00 AM EST - 1 year ago

Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial

Jan 6, 2025, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

Dec 16, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 4:30 PM EST - 1 year ago

Arcturus Therapeutics Holdings Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 4:30 AM EST - 1 year ago

Arcturus Therapeutics Holdings Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 8:00 PM EST - 1 year ago

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Nov 14, 2024, 1:00 AM EST - 1 year ago

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Nov 11, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Nov 7, 2024, 4:30 PM EST - 1 year ago

Arcturus Therapeutics Holdings Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

Oct 31, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

Sep 18, 2024, 8:00 AM EDT - 1 year ago

Arcturus Therapeutics Holdings Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 13, 2024, 8:15 AM EDT - 1 year ago

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Sep 9, 2024, 11:00 AM EDT - 1 year ago

Arcturus Therapeutics Holdings Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 4, 2024, 3:00 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Transcript: 2024 Wells Fargo Healthcare Conference

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

Aug 27, 2024, 5:00 PM EDT - 1 year ago

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Aug 13, 2024, 9:30 AM EDT - 1 year ago

Arcturus Therapeutics Holdings Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 5, 2024, 4:30 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Earnings Call Transcript: Q2 2024

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference

Jul 18, 2024, 7:30 PM EDT - 1 year ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024

Jul 1, 2024, 4:01 PM EDT - 2 years ago

Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs

Jun 20, 2024, 8:00 AM EDT - 2 years ago

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

Jun 7, 2024, 10:30 AM EDT - 2 years ago

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference

May 28, 2024, 6:30 AM EDT - 2 years ago

Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

May 20, 2024, 8:30 AM EDT - 2 years ago

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

May 8, 2024, 4:30 PM EDT - 2 years ago

Arcturus Therapeutics Holdings Earnings Call Transcript: Q1 2024

May 8, 2024, 4:01 PM EDT - 2 years ago

Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress

Apr 25, 2024, 4:01 PM EDT - 2 years ago

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024

Mar 14, 2024, 11:45 AM EDT - 2 years ago

Arcturus Therapeutics Holdings Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Mar 7, 2024, 4:30 PM EST - 2 years ago

Arcturus Therapeutics Holdings Earnings Call Transcript: Q4 2023

Mar 7, 2024, 4:01 PM EST - 2 years ago

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

Feb 26, 2024, 9:00 AM EST - 2 years ago

Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference

bigchouse May. 13 at 9:10 AM

0 · Reply

bigchouse May. 13 at 12:13 AM

0 · Reply

2PacalypseNow4Life May. 12 at 8:34 PM

1 · Reply

SuperGreenToday May. 12 at 7:13 PM

0 · Reply

Dr_Feel_Good May. 12 at 6:33 PM

1 · Reply

Choice79 May. 12 at 1:42 PM

$ARCT highly unlikely that Arct will work on the hantavirus. Costs a lot of money to start something like that and they are prioritizing all their cash on otc and cf.

1 · Reply

bigchouse May. 12 at 8:33 AM

0 · Reply

bigchouse May. 12 at 3:03 AM

$ARCT https://virological.org/t/complete-sequence-of-orthohantavirus-andesense-virus-swiss-resident-2026/1023

1 · Reply

OfficialStocktwitsUser May. 11 at 10:43 PM

0 · Reply

bigchouse May. 11 at 4:05 PM

0 · Reply

wahoowa96 May. 11 at 2:21 PM

$ARCT Arcturus can definitely work out Hantavirus vaccines...we are the only one still developing mRNA based bird flu vaccines almost to finish phase 1 of ARCT-2304. https://ctv.veeva.com/study/safety-and-immunogenicity-study-of-self-amplifying-rna-pandemic-influenza-vaccine-in-adults

0 · Reply

bigchouse May. 10 at 11:05 PM

$ARCT The U.S. Centers for Disease Control and Prevention (CDC) said on May 8 that Americans aboard the MV Hondius, the cruise ship at the center of a hantavirus outbreak, will be sent to a quarantine center in Nebraska. The Dutch-flagged cruise ship, which has 17 Americans onboard, is expected to dock in Tenerife in Spain’s Canary Islands on May 10, according to tour operator Oceanwide Expeditions. https://archive.ph/xjtbG

0 · Reply

bigchouse May. 10 at 8:21 PM

$ARCT Document at the link. Statement from the International Hantavirus Society and members of the international hantavirus research and clinical community regarding Andes virus transmission and the current outbreak investigation. https://zenodo.org/records/20095475

0 · Reply

bigchouse May. 10 at 8:13 PM

$ARCT Hantavirus in Spain: why was quarantine imposed? The Spanish authorities reacted swiftly to the threat of the infection spreading. At the government’s request, the Central Court of Madrid ordered the compulsory isolation of 14 Spanish citizens who had travelled on the MV Hondius and may have come into contact with the pathogen. https://visitukraine.today/blog/8409/hantavirus-outbreak-spain-is-the-first-country-to-impose-a-lockdown-due-to-the-new-disease#symptoms-of-hantavirus-how-is-it-transmitted-and-why-is-it-dangerous

0 · Reply

bigchouse May. 10 at 4:36 AM

$ARCT I don't go on cruises. Over 100 Passengers and Crew Stricken with Highly Contagious Norovirus on Caribbean Princess Cruise Ship https://www.thegatewaypundit.com/2026/05/100-passengers-crew-stricken-highly-contagious-norovirus-caribbean/

0 · Reply

Dr_Feel_Good May. 9 at 4:06 AM

$ARCT SOLID recovery today to refill that gap on rhe 5 day - post earnings. Have a good weekend fam.

1 · Reply

bigchouse May. 8 at 10:26 PM

$ARCT Not Arcturus. Patent for mRNA Vaccines Against H antavirus Patent US-2025127870-A1 Inventor BUKREYEV ALEXANDER (US) GARCIA-BLANCO MARIANO (US) KUZMIN IVAN (US) ACOSTA RUBEN SOTO (US) Assignee UNIV TEXAS (US) https://pubchem.ncbi.nlm.nih.gov/patent/US-2025127870-A1

2 · Reply

2PacalypseNow4Life May. 8 at 9:43 PM

$ARCT "(...)Management highlighted that unlike competitors, they do not require steroids for co-treatment and have been cleared for unsupervised at-home dosing. The distinction is attributed to a different lipid chemistry and a proprietary manufacturing process that removes specific impurities causing immunogenicity. " What can i say. CC was great. But nobody asked about ongoin trial. Or.i missed sth?

2 · Reply

wahoowa96 May. 8 at 5:32 PM

$ARCT That's all you have bears?

0 · Reply

StocksnewbieRo May. 8 at 3:49 PM

$ARCT let’s go back baby

0 · Reply

Choice79 May. 8 at 3:30 PM

$ARCT green!!

0 · Reply

Choice79 May. 8 at 1:31 PM

$ARCT over 6 million shares are shorted. At some point they will have to cover and it will be explosive when they do.

1 · Reply

Market Cap	245.43M
Revenue (ttm)	82.03M
Net Income (ttm)	-65.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-80.19%
Debt to Equity Ratio	0.00

Volume	689,600
Avg Vol	484,998
Day's Range	N/A - N/A
Shares Out	28.42M
Stochastic %K	23%
Beta	2.43
Analysts	Strong Sell
Price Target	$18.33